Taysha Gene Therapies, Inc.

TSHA · XNAS

CIK 1806310fmd_1RJCBQZ0DND92J7J7G3TCGWS8MManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.